.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Julphar
Novartis
Cantor Fitzgerald
McKesson
AstraZeneca
McKinsey
Harvard Business School
Baxter
Fuji

Generated: September 26, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205625

« Back to Dashboard
NDA 205625 describes ARNUITY ELLIPTA, which is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug. Additional details are available on the ARNUITY ELLIPTA profile page.

The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.

Summary for NDA: 205625

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:8
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 205625

Suppliers and Packaging for NDA: 205625

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ARNUITY ELLIPTA
fluticasone furoate
POWDER;INHALATION 205625 NDA GlaxoSmithKline LLC 0173-0874 0173-0874-10 1 INHALER in 1 CARTON (0173-0874-10) > 30 POWDER in 1 INHALER
ARNUITY ELLIPTA
fluticasone furoate
POWDER;INHALATION 205625 NDA GlaxoSmithKline LLC 0173-0874 0173-0874-14 1 INHALER in 1 CARTON (0173-0874-14) > 14 POWDER in 1 INHALER

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INHALATIONStrength0.1MG/INH
Approval Date:Aug 20, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 20, 2017
Regulatory Exclusivity Use:NEW PRODUCT
Patent:► SubscribePatent Expiration:Aug 3, 2021Product Flag?YSubstance Flag?YDelist Request?
Patented Use:INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER
Patent:► SubscribePatent Expiration:Aug 3, 2021Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 205625

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline
ARNUITY ELLIPTA
fluticasone furoate
POWDER;INHALATION205625-001Aug 20, 2014► Subscribe► Subscribe
Glaxosmithkline
ARNUITY ELLIPTA
fluticasone furoate
POWDER;INHALATION205625-002Aug 20, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Cipla
Dow
McKesson
Federal Trade Commission
US Department of Justice
Citi
Chubb
Express Scripts
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot